Pitolisant hydrochloride is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated in hypersomnia and narcolepsy-cataplexy syndrome. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Wakix (TN) and Ciproxidine. Its PubChem CID is 11551689.
Pitolisant hydrochloride
| CAS No | 903576-44-3 |
|---|---|
| Molecular Formula | C17H27Cl2NO |
| Molecular Weight | 332.3 g/mol |
| Synonyms | 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine;hydrochloride |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Pitolisant hydrochloride is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and is indicated in hypersomnia and narcolepsy-cataplexy syndrome.
The listed CAS number is 903576-44-3.
The listed molecular formula is C17H27Cl2NO.
The listed molecular weight is 332.3 g/mol.
1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine;hydrochloride.
The source lists Wakix (TN) and Ciproxidine.